Skin collagen fluorophore LW-1 versus skin fluorescence as markers for the long-term progression of subclinical macrovascular disease in type 1 diabetes

Cardiovascular Diabetology

Volumn 15, Issue 1, 2016, Pages

  Sell, David R ^a   Sun, Wanjie ^b   Gao, Xiaoyu ^b   Strauch, Christopher ^a   Lachin, John M ^b   Cleary, Patricia A ^b   Genuth, Saul ^a   Monnier, Vincent M ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Glycation; HbA1c; Nephropathy; Neuropathy; Retinopathy; Skin autofluorescence

Indexed keywords

ALBUMIN; COLLAGEN; GLUCOSE; HEMOGLOBIN A1C; SKIN COLLAGEN; UNCLASSIFIED DRUG; ADVANCED GLYCATION END PRODUCT; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; DNA BINDING PROTEIN; HEAT SHOCK PROTEIN; HSFX1 PROTEIN, HUMAN;

ADULT; AGE DISTRIBUTION; ALLOPATHY; ARTERIAL WALL THICKNESS; ARTICLE; CHROMATOGRAPHY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; CORONARY ARTERY CALCIUM SCORE; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; FLUORESCENCE; FOREARM; GLUCOSE BLOOD LEVEL; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; INTENSIVE CARE; INTERMETHOD COMPARISON; LOGISTIC REGRESSION ANALYSIS; LONG WAVELENGTH FLUORESCENCE; MACROVASCULAR DISEASE; MAJOR CLINICAL STUDY; MICROANEURYSM; MICROANGIOPATHY; MYOCARDIAL DISEASE; NON INVASIVE PROCEDURE; RETINOPATHY; RISK FACTOR; SKIN BIOPSY; SKIN INTRINSIC FLUORESCENCE; SKIN LINKED FLUORESCENCE; YOUNG ADULT; AGE; BIOPSY; CAROTID ARTERY DISEASES; CLINICAL TRIAL; COMPLICATION; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; FLUOROMETRY; HYPERTROPHY, LEFT VENTRICULAR; LUMINESCENCE; METABOLISM; PREDICTIVE VALUE; RISK ASSESSMENT; SKIN; TANDEM MASS SPECTROMETRY; TIME FACTOR;

AGE FACTORS; BIOMARKERS; BIOPSY; CAROTID ARTERY DISEASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DISEASE PROGRESSION; DNA-BINDING PROTEINS; FLUOROMETRY; FOREARM; GLYCOSYLATION END PRODUCTS, ADVANCED; HEAT-SHOCK PROTEINS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; HYPOGLYCEMIC AGENTS; LUMINESCENT MEASUREMENTS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS; SKIN; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 84957881493     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-016-0343-3     Document Type: Article

References (52)

1. Sell D, Monnier V. Molecular basis of arterial stiffening: role of glycation-a mini-review. Gerontology. 2012;58:227-37.
2. Monnier VM, Kohn RR, Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc Natl Acad Sci USA. 1984;81:583-7.
3. Monnier VM, Vishwanath V, Frank KE, Elemts CA, Dauchot P, Kohn RR. Relation between complications of type 1 diabetes mellitus and collagen-linked fluorescence. N Engl J Med. 1986;314:403-8.
4. Thomas MC, Forbes JM, MacIsaac R, Jerums G, Cooper ME. Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more? Ann NY Acad Sci. 2005;1043:644-54.
5. Kikugawa K, Beppu M. Involvement of lipid oxidation products in the formation of fluorescent and crosslinked proteins. Chem Phys Lipids. 1987;44:277-96.
6. Breunig HG, Studier H, König K. Multiphoton excitation characteristics of cellular fluorophores of human skin in vivo. Opt Express. 2010;18:7857-71.
7. Croce AC, Ferrigno A, Piccolini VM, Tarantola E, Boncompagni E, Bertone V, Milanesi G, Freitas I, Vairetti M, Bottiroli G. Integrated autofluorescence characterization of a modified-diet liver model with accumulation of lipids and oxidative stress. Biomed Res Int. 2014;2014:803491.
8. Conway BN, Aroda VR, Maynard JD, Matter N, Fernandez S, Ratner RE, Orchard TJ. Skin intrinsic fluorescence correlates with autonomic and distal symmetrical polyneuropathy in individuals with type 1 diabetes. Diabetes Care. 2011;34:1000-5.
9. Sugisawa E, Miura J, Iwamoto Y, Uchigata Y. Skin autofluorescence reflects integration of past long-term glycemic control in patients with type 1 diabetes. Diabetes Care. 2013;36:2339-45.
10. Maynard JD, Rohrscheib M, Way JF, Nguyen CM, Ediger MN. Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetes Care. 2007;30:1120-4.
11. Januszewski AS, Sachithanandan N, Karschimkus CS, O'Neal DN, Yeung CK, Alkatib N, Jenkins AJ. Non-invasive measures of tissue autofluorescence are increased in type 1 diabetes complications and correlate with a non-invasive measure of vascular dysfunction. Diabet Med. 2012;29:726-33.
12. den Engelsen C, van den Donk M, Gorter KJ, Salomé PL, Rutten GE. Advanced glycation end products measured by skin autofluorescence in a population with central obesity. Dermatoendocrinol. 2012;4:33-8.
13. Ueno H, Koyama H, Tanaka S, Fukumoto S, Shinohara K, Shoji T, Emoto M, Tahara H, Kakiya R, Tabata T, et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism. 2008;57:1452-7.
14. Fu M, Knecht K, Thorpe S, Baynes J. Role of oxygen in cross-linking and chemical modification of collagen by glucose. Diabetes. 1992;41(Suppl 2):42-8.
15. Sell DR, Nemet I, Monnier VM. Partial characterization of the molecular nature of collagen-linked fluorescence: role of diabetes and end-stage renal disease. Arch Biochem Biophys. 2010;493:192-206.
16. Krolewski AS, Kosinski EJ, Warram JH, Leland OS, Busick EJ, Asmal AC, Rand LI, Christlieb AR, Bradley RF, Kahn CR. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol. 1987;59:750-5.
17. Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund JY, Zinman B, Jacobson A, Sun W, Lachin JM, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study. Diabetes. 2006;55:3556-65.
18. Cleary PA, Braffett B, Orchard T, Lyons TJ, Maynard J, Cowie C, Gubitosi-Klug RA, Way J, Anderson K, Barnie A, et al. Clinical and technical factors associated with skin intrinsic fluorescence in subjects with type 1 diabetes from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabetes Technol Ther. 2013;15:466-74.
19. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, Cleary PA, Lachin J, Genuth S. Skin collagen glycation, glycoxidation and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT Skin Collagen Ancillary Study Group. Diabetes Control and Complications Trial. Diabetes. 1999;48:870-80.
20. Monnier VM, Sell DR, Strauch C, Sun W, Lachin JM, Cleary PA, Genuth S, DCCT Research Group. The association between skin collagen glucosepane and past progression of microvascular and neuropathic complications in type 1 diabetes. J Diabetes Complications. 2013;27:141-9.
21. The DCCT Research Group. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
22. The DCCT/EDIC Research Group. Effect of intensive diabetes therapy on the progression of diabetic retinopathy in patients with type 1 diabetes: 18 years of follow-up in the DCCT/EDIC. Diabetes. 2015;64:631-42.
23. Fan X, Sell DR, Zhang J, Nemet I, Theves M, Lu J, Strauch C, Halushka MK, Monnier VM. Anaerobic vs aerobic pathways of carbonyl and oxidant stress in human lens and skin during aging and in diabetes: a comparative analysis. Free Radic Biol Med. 2010;49:847-56.
24. Stegeman H, Stalder S. Determination of hydroxyproline. Clin Chim Acta. 1967;18:267-73.
25. Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J. 2003;375:581-92.
26. Orchard TJ, Lyons TJ, Cleary PA, Braffett BH, Maynard J, Cowie C, Gubitosi-Klug RA, Way J, Anderson K, Barnie A, et al. The association of skin intrinsic fluorescence with type 1 diabetes complications in the DCCT/EDIC study. Diabetes Care. 2013;36:3146-53.
27. Conway B, Edmundowicz D, Matter N, Maynard J, Orchard T. Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes. Diabetes Technol Ther. 2010;12:339-45.
28. Hull EL, Ediger MN, Unione AHT, Deemer EK, Stroman ML, Baynes JW. Noninvasive, optical detection of diabetes: model studies with porcine skin. Opt Express. 2004;12:4496-510.
29. Noordzij MJ, Lefrandt JD, Graaff R, Smit AJ. Dermal factors influencing measurement of skin autofluorescence. Diabetes Technol Ther. 2011;13:165-70.
30. The DCCT/EDIC Research Group. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348:2294-303.
31. Turkbey EB, Backlund JY, Genuth S, Jain A, Miao C, Cleary PA, Lachin JM, Nathan DM, van der Geest RJ, Soliman EZ, et al. Myocardial structure, function, and scar in patients with type 1 diabetes mellitus. Circulation. 2011;124:1737-46.
32. Genuth S, Sun W, Cleary P, Gao X, Sell DR, Lachin J, DCCT/EDIC Research Group, Monnier VM. Skin advanced glycation endproducts (AGEs) glucosepane and methylglyoxal hydroimidazolone are independently associated with long-term microvascular complication progression of type 1 diabetes. Diabetes. 2015;64:266-78.
33. Hofmann B, Adam AC, Jacobs K, Riemer M, Erbs C, Bushnaq H, Simm A, Silber RE, Santos AN. Advanced glycation end product associated skin autofluorescence: a mirror of vascular function? Exp Gerontol. 2013;48:38-44.
34. Pageon H, Zucchi H, Rousset F, Monnier VM, Asselineau D. Skin aging by glycation: lessons from the reconstructed skin model. Clin Chem Lab Med. 2014;52:169-74.
35. Monnier VM, Sun W, Gao X, Sell DR, Cleary PA, Lachin JM, Genuth S, The DCCT/EDIC Research Group. Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Cardiovasc Diabetol. 2015;14:118.
36. Balla S, Nusair MB, Alpert MA. Risk factors for atherosclerosis in patients with chronic kidney disease: recognition and management. Curr Opin Pharmacol. 2013;13:192-9.
37. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS, CREED Investigators. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol. 2001;12:2768-74.
38. Conway BN, Aroda VR, Maynard JD, Matter N, Fernandez S, Ratner RE, Orchard TJ. Skin intrinsic fluorescence is associated with coronary artery disease in individuals with long duration of type 1 diabetes. Diabetes Care. 2012;35:2331-6.
39. Meerwaldt R, Links TP, Graaff R, Hoogenberg K, Lefrandt JD, Baynes JW, Gans RO, Smit AJ. Increased accumulation of skin advanced glycation end-products precedes and correlates with clinical manifestation of diabetic neuropathy. Diabetologia. 2005;48:1637-44.
40. Hu H, Han CM, Hu XL, Ye WL, Huang WJ, Smit AJ. Elevated skin autofluorescence is strongly associated with foot ulcers in patients with diabetes: a cross-sectional, observational study of Chinese subjects. J Zhejiang Univ Sci B. 2012;13:372-7.
41. Chabroux S, Canouï-Poitrine F, Reffet S, Mills-Joncour G, Morelon E, Colin C, Thivolet C. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. Diabetes Metab. 2010;36:152-7.
42. Gerrits EG, Lutgers HL, Kleefstra N, Graaff R, Groenier KH, Smit AJ, Gans RO, Bilo HJ. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care. 2008;31:517-21.
43. Genuth S, Sun W, Cleary P, Sell DR, Dahms W, Malone J, Sivitz W, Monnier VM, DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications participants with type 1 diabetes. Diabetes. 2005;54:3104-11.
44. Meerwaldt R, Hartog JW, Graaff R, Huisman RJ, Links TP, den Hollander NC, Thorpe SR, Baynes JW, Navis G, Gans RO, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:3687-93.
45. Aroda VR, Conway BN, Fernandez SJ, Matter NI, Maynard JD, Orchard TJ, Ratner RE. Cross-sectional evaluation of noninvasively detected skin intrinsic fluorescence and mean hemoglobin A1C in type 1 diabetes. Diabetes Technol Ther. 2013;15:117-23.
46. Noordzij MJ, Mulder DJ, Oomen PHN, Brouwer T, Jager J, Castro Cabezas M, Lefrandt JD, Smit AJ. Skin autofluorescence and risk of micro- and macrovascular complications in patients with type 2 diabetes mellitus-a multi-centre study. Diabet Med. 2012;29:1556-61.
47. Bos DC, de Ranitz-Greven WL, de Valk HW. Advanced glycation end products, measured as skin autofluorescence and diabetes complications: a systematic review. Diabetes Technol Ther. 2011;13:1-7.
48. Noordzij MJ, Lefrandt JD, Loeffen EAH, Saleem BR, Meerwaldt R, Lutgers HL, Smit AJ, Zeebregts CJ. Skin autofluorescence is increased in patients with carotid artery stenosis and peripheral artery disease. Int J Cardiovasc Imaging. 2012;28:431-8.
49. Meerwaldt R, Graaff R, Oomen PH, Links TP, Jager JJ, Alderson NL, Thorpe SR, Baynes JW, Gans RO, Smit AJ. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia. 2004;47:1324-30.
50. Eny KM, Lutgers HL, Maynard J, Klein BE, Lee KE, Atzmon G, Monnier VM, van Vliet-Ostaptchouk JV, Graaff R, van der Harst P, et al. GWAS identifies an NAT2 acetylator status tag single nucleotide polymorphism to be a major locus for skin fluorescence. Diabetologia. 2014;57:1623-34.
51. Roshandel D, Klein R, Klein B, Wolffenbuttel H, Atzmon G, Crandall J, Barzilai N, Bull S, Canty A, Hosseini S et al. A locus associated with skin intrinsic fluorescence in type 1 diabetes. In press. 2016.
52. Eny KM, Orchard TJ, Miller RG, Maynard J, Grant DM, Costacou T, Cleary PA, Braffett BH, The DCCT/EDIC Research Group, Paterson AD. Caffeine consumption contributes to skin intrinsic fluorescence in type 1 diabetes. Diabetes Technol Ther. 2015;17:726-34.